Abstracts tagged "Arteriosclerosis"

Abstract Number: 470 • 2018 ACR/ARHP Annual Meeting
Pro-Inflammatory High Density Lipoprotein Function Is Associated with Accelerated Carotid Intimal Medial Thickness Progression in Childhood-Onset SLE
Jennifer C. Cooper¹, Stacy P. Ardoin², Emily von Scheven³, Laura E. Schanberg⁴, Brian Skaggs⁵ and Maureen A. McMahon⁶, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ³Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Patients with childhood-onset(cSLE) are at significantly increased risk of death from cardiovascular disease when they reach early adulthood. The Atherosclerosis Prevention Pediatric Lupus Erythematous…
Abstract Number: 494 • 2018 ACR/ARHP Annual Meeting
Arterial Wall Inflammation Declines after 6 Months of Anti-Inflammatory Therapy with Methotrexate and/or Adalimumab in Rheumatoid Arthritis Patients
Annelies Blanken¹, Rabia Agca¹, Alexandre Voskuyl², Ronald Boellaard³, Conny van der Laken² and Michael Nurmohamed^2,4, ¹Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, ³Radiology and Nuclear Medicine, Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, mostly explained by both an increased prevalence of traditional CV risk factors…
Abstract Number: 707 • 2018 ACR/ARHP Annual Meeting
Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus
Monica Vazquez-Del Mercado^1,2, Felipe Perez-Vazquez³, Eduardo Gomez-Bañuelos¹, Efrain Chavarria-Avila³, Arcelia Llamas-Garcia⁴, Karla I. Arrona-Rios⁴, Gustavo I Diaz-Rubio³, Sergio Duran-Barragan⁴, Rosa E Navarro-Hernandez³, Bethel Jordan-Estrada³, Natalia Prado-Bachega⁵, Miguel A. A. Gonzalez-Beltran³, Carlos G Ramos-Becerra⁶, Fernando Grover-Paez⁶, David Cardona-Muller⁷ and Ernesto German Cardona-Muñoz⁷, ¹Servicio de Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ²Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Mexico, ³Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁴Servicio en Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁵Anesthesiology, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁶Centro Universitario de Ciencias de la Salud, INTEC, Universidad de Guadalajara, Guadalajara, Mexico, ⁷Departamento de Fisiología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico
Background/Purpose: It is well known that cardiovascular diseases (CVD) are a major contributor of death in systemic lupus erythematosus (SLE) as well in other rheumatic…
Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting
Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
Linh Truong¹, Nicole Ridolfi¹ and Maida Wong^2,3, ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Department of Medicine, University of California, Irvine, orange, CA, ³Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA
Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…
Abstract Number: 2689 • 2018 ACR/ARHP Annual Meeting
Association between Small Vessel Disease and Arterial Stiffness in Systemic Sclerosis
Stergios Soulaidopoulos¹, Eleni Pagkopoulou¹, Eva Triantafyllidou¹, Niki Katsiki², George D. Kitas^3,4, Asterios Karagiannis², Alexandros Garyfallos¹ and Theodoros Dimitroulas¹, ¹Fourth Department of Internal Medicine, Hippokration University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Second Department of Propaedeutic Internal Medicine, Hippokration University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, ³Department of Rheumatology, Dudley Group of Hospitals, NS Foundation Trust, Dudley, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom
Background/Purpose: Microangiopathy predominates in the pathophysiology of Systemic Sclerosis (SSc). However, large vessel involvement leading to higher risk for cardiovascular disease in SSc remains unclear.…
Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Panagiota Anyfanti¹, Eugenia Gkaliagkousi¹, Areti Triantafyllou¹, Eleni Gavriilaki¹, Panagiotis Dolgyras¹, Sophia Chatzimichailidou², Vasiliki Galanopoulou³, Stella Douma¹ and Spyros Aslanidis², ¹3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ²Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ³Rheumatology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece
Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…
Abstract Number: 1487 • 2016 ACR/ARHP Annual Meeting
Comparison Between Intima-Media Thickness and Coronary Artery Tomography in Subclinical Atheroesclerosis Detection in Rheumatoid Arthritis
Carlos Fernández-Díaz¹, Lucia Cristina Domínguez-Casas¹, Leyre Riancho-Zarrabeitia¹, Alfonso Corrales¹, José Antonio Parra², Virginia Portilla³, Montserrat Santos-Gómez⁴, Patrick H Dessein⁵, Ricardo Blanco¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Radiology Division, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Intima media thickness (IMT) and coronary artery calcification (CAC) quantification using multidetector computed tomography (MDCT) scanner are useful in detecting subclinical atherosclerosis and…
Abstract Number: 2580 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients
Kensuke Kume¹, Kanzo Amano², Susumu Yamada¹, Toshikatsu Kanazawa³, Kazuhiko Hatta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular　prevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: 225 • 2015 ACR/ARHP Annual Meeting
Gout Patients Present Carotid Plaques at Presentation in Spite of Low-Risk Cardiovascular Score
Mariano Andrés¹, Francisca Sivera², José Antonio Bernal¹, Neus Quilis¹, Loreto Carmona³, Paloma Vela^1,4 and Eliseo Pascual^1,4, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ³Instituto de Salud Musculoesquelética, Madrid, Spain, ⁴Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Gout patients present carotid plaques at presentation in spite of low-risk cardiovascular score.Background/Purpose: Gout is associated with an increased cardiovascular (CV) risk related to high…
Abstract Number: 486 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Improves Arterial Stiffness Despite up-Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada², Toshikatsu Kanazawa³, Hiroshi Komori⁴, Kazuhiko Hatta⁵, Kuniki Amano⁶ and Noriko Kuwaba⁷, ¹20-16 Higashi Kannon, Nishi Ward, hiroshima clinic, Hiroshima, Japan, ²Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴internal medicine, hiroshima clinic, hiroshima, Japan, ⁵Rheumatology, Hatta Clinic, Kure, Japan, ⁶Rheumatology, Sky Clinic, Hiroshima, Japan, ⁷Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascularprevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: 2672 • 2013 ACR/ARHP Annual Meeting
Associations Between Popliteal Artery Wall Thickness and Knee Structure In Adults Without Clinical Knee Disease: A Prospective Cohort Study
Yuanyuan Wang¹, Diaz Novera¹, Anita Wluka², Jessica Fairley¹, Graham Giles³, Richard O'Sullivan⁴, Andrew Teichtahl⁵ and Flavia Cicuttini², ¹Monash University, Melbourne, Australia, ²Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³University of Melbourne, Melbourne, Australia, ⁴Epworth Hospital, Melbourne, Australia, ⁵Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Background/Purpose: There is evidence for a vascular contribution to the pathogenesis of osteoarthritis. The aim of this study was to examine the association between popliteal…
Abstract Number: 1253 • 2012 ACR/ARHP Annual Meeting
Identifying Vulnerable Plaque in Rheumatoid Arthritis: A Pilot Study Using Novel Microbubble-Contrast Enhanced Carotid Ultrasonography
Kimberly P. Liang¹, Douglas P. Landsittel², Suresh R. Mulukutla³, Steven E. Reis⁴, Marc C. Levesque¹, Flordeliza S. Villanueva³, Hunter C. Champion⁵ and Larry W. Moreland¹, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ³Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is independently associated with a higher risk of cardiovascular disease (CVD). Markers of systemic inflammation, as seen in RA, are associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].